ERDHEIM-CHESTER DISEASE
Clinical trials for ERDHEIM-CHESTER DISEASE explained in plain language.
Never miss a new study
Get alerted when new ERDHEIM-CHESTER DISEASE trials appear
Sign up with your email to follow new studies for ERDHEIM-CHESTER DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a melanoma drug combo tame rare BRAF cancers?
Disease control Recruiting nowThis trial is testing two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific genetic change called BRAF V600 mutation. The goal is to see if the combination can shrink tumors or stop them from growing. About 3…
Matched conditions: ERDHEIM-CHESTER DISEASE
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Targeted drug cobimetinib tested for rare immune cell cancers
Disease control Recruiting nowThis phase 2 study tests the drug cobimetinib in children and adults with Langerhans cell histiocytosis and related disorders that have come back or not responded to standard treatment. Cobimetinib blocks a growth signal that goes haywire in these diseases. The study will enroll …
Matched conditions: ERDHEIM-CHESTER DISEASE
Phase: PHASE2 • Sponsor: Carl Allen • Aim: Disease control
Last updated Jun 26, 2026 17:51 UTC
-
Massive study tracks hidden toll of rare immune diseases
Knowledge-focused Recruiting nowThis study follows 6,000 people with histiocytic disorders (like Langerhans cell histiocytosis) to understand long-term health problems, pain, mental health, and causes of death. Researchers compare participants to healthy controls to identify factors that lead to new health issu…
Matched conditions: ERDHEIM-CHESTER DISEASE
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
New PET tracer could spot Hard-to-See cancers
Knowledge-focused Recruiting nowThis early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it shows up on PET/CT scans in people with certain blood cancers (like multiple myeloma and non-Hodgkin lymphoma) and rare immune cell tumors. About 30 participants will get the agent a…
Matched conditions: ERDHEIM-CHESTER DISEASE
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New registry aims to unlock mysteries of rare histiocyte disorders
Knowledge-focused Recruiting nowThis study creates a registry for people with Erdheim-Chester disease and related histiocytoses. Researchers will collect medical information and patient experiences over time to better understand these rare conditions. Up to 500 participants will be enrolled, and some may be ask…
Matched conditions: ERDHEIM-CHESTER DISEASE
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC